MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10507256261454542

Медицинская библиотека · Thyroid : official journal of the American Thyroid Association · 2026

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Marchesi Silvia, Romanò Rebecca, Spagnoletti Andrea, Barretta Francesco, Buriolla Silvia, De Monte Matteo, Sciortino Carolina, Demurtas Sara, Meschia Lorenzo, Nuzzolese Imperia, Bergamini Cristiana, Cavalieri Stefano, Colombo Elena, Ottini Arianna, Miceli Rosalba, Salvetti Monica, Paolini Biagio, Guidetti Anna, Carpenedo Monica, Licitra Lisa, Locati Laura Deborah, Alfieri Salvatore

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Antiangiogenic and targeted therapies represent the most effective systemic options for advanced thyroid cancers. In this setting, toxicity management is essential to ensure treatment adherence. Among hematological toxicities, erythrocytosis has been rarely investigated, and its clinical pattern and management remain unclear.

MATERIALS AND

METHODS

We conducted a retrospective cohort study including patients with any advanced thyroid cancer histology treated with antiangiogenic or targeted therapies between 2012 and 2023 at two Italian referral centers. Therapies included RET inhibitors (RETi: selpercatinib, pralsetinib), cabozantinib, the BRAF/MEK inhibitor combination dabrafenib + trametinib, lenvatinib, sorafenib, and vandetanib. Erythrocytosis, defined according to 2022 World Health Organization criteria, was assessed through serial hemoglobin and hematocrit measurements up to 36 months from treatment start. Associations with clinical variables, event-free survival (EFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and acute vascular events were assessed using Fisher's exact and regression models, as appropriate.

RESULTS

Among 173 screened patients, 135 were included in the final analysis (median follow-up 68.5 months). Erythrocytosis occurred in 24 patients (17.8%), with 16/24 (66.6%) experiencing recurrent events (total: 50). Median time to onset was 1.28 months (Q1-Q3: 0.76-5.14). RETi showed the highest incidence (46.7%), followed by vandetanib (20.7%). Among 14/24 tested patients, no JAK2 V617F or exon 12 alterations were detected. Management involved temporary treatment interruption in 60.0% (30/50) of events, with 53.3% (16/30) resuming at a reduced dose; in selected cases (4/9, 44.4%), hematology-guided phlebotomy was performed without drug discontinuation. Erythrocytosis was not associated with EFS, OS, or ORR, but was associated with higher DCR (p = 0.031). Incidence of acute vascular events was comparable among patients with (8.3%) and without (14.4%) erythrocytosis.

CONCLUSIONS

Erythrocytosis represents an underrecognized, early, recurrent, and indolent adverse event of antiangiogenic and targeted therapies, particularly RETi, in advanced thyroid cancer. Its biological mechanisms and optimal management strategies warrant further investigation.

Для цитирования: Marchesi Silvia, Romanò Rebecca, Spagnoletti Andrea, Barretta Francesco, Buriolla Silvia, De Monte Matteo, Sciortino Carolina, Demurtas Sara, Meschia Lorenzo, Nuzzolese Imperia, Bergamini Cristiana, Cavalieri Stefano, Colombo Elena, Ottini Arianna, Miceli Rosalba, Salvetti Monica, Paolini Biagio, Guidetti Anna, Carpenedo Monica, Licitra Lisa, Locati Laura Deborah, Alfieri Salvatore. Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.. Thyroid : official journal of the American Thyroid Association. 2026. DOI: 10.1177/10507256261454542.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.